Background: Monitoring L-asparagine (L-ASN) plasma levels could provide information useful for determining whether the dosage or schedule of L-asparaginase (L-ASE) administration is adequate. Very few data are available on depletion caused by the Erwinia chrysanthemi (E. chrysanthemi) product. Since it has been suggested that L-ASN depletion may have been overestimated in the past due to residual L-ASE activity, samples in this study have been analyzed after deproteinization with sulphosalicylic acid. Patients undergoing subsequent exposures to L-ASE derived from E. chrysanthemi have been investigated.
Introduction
L-Asparaginase (L-ASE) is an enzyme that catalyzes the hydrolysis of L-asparagine (L-ASN) to L-aspartate and ammonia [1] . L-ASE should produce a long-lasting depletion of L-ASN to selectively inhibit protein synthesis in cells which are unable to synthesize L-ASN [2] .
Due to the specificity of its mechanism of action, L-ASE is widely used for the treatment of acute lymphoblastic leukemia (ALL) and lymphomas [3] ; lymphocytic leukemia cells in fact do not express L-ASN synthase [4] and thus are unable to synthesize L-ASN, whereas the majority of normal tissues and other neoplastic cells express very high levels of L-ASN synthase.
Prolonged treatment with conventional doses of L-ASE derived from Escherichia coli (E. coll) have been shown to cause a fall of the plasma L-ASN levels [5] . Other studies have also found a relationship between L-ASN depletion in plasma and in cerebro-spinal fluid (CSF) in animals and in humans treated with L-ASE [6] . Theoretically, monitoring L-ASN plasma levels should be a valuable tool for evaluating whether the dosage-schedule of L-ASE is adequate in all patients. Asselin et al. have, however, demonstrated the presence of a residual level of L-ASE activity in blood drawn from patients under treatment with the enzyme and showed that L-ASN hydrolysis may go on during blood centrifugation and even after storage of plasma at -80 °C [7] . It was thus suggested that L-ASN depletion in the plasma of patients treated with L-ASE may be overestimated. Accordingly, L-ASE inhibitors, such as DONV, have been used to neutralise this residual L-ASE activity [8] . Since these inhibitors are highly unstable, a new procedure, based on the rapid deproteinization of blood by the addition of sulphosalicylic acid (SSA), was established in our laboratory [9] . This paper will present data on the depletion of L-ASN in the plasma and in the CSF of children with ALL during subsequent exposures to Erwinia chrysanthemi (E. chrysanthemi) derived from L-ASE, and given at different doses and schedules, and the results of an experiment developed to test for the presence of residual L-ASE activity and of L-ASE inhibitors in the plasma.
Patients and methods

Patient eligibility and treatment schedules
Fifty-four children diagnosed with ALL in our institution and enrolled in the national AIEOP-ALL 91 trial, entered this study [10] .The patients were stratified into standard risk (SR), intermediate risk (IR) and high risk (HR) groups according to their presenting features. The treatment schedule was a modified version of the BFM-ALL 86 study [11] and included induction, consolidation, reinduction and maintenance phases. As shown in Table 1 , L-ASE was given to all SR and IR patients (first exposure) at conventional doses (10,000 IU/sqm) every three days starting on day 18 of the induction phase (8 doses). SR patients were then given (second exposure) L-ASE at the same doses twice a week (4 doses) during the reinduction phase and were randomized at the beginning of the maintenance phase to receive (third exposure) or not high-dose (HD) L-ASE (i.e., 25,000 IU/sqm) weekly, for a total of 20 doses. IR patients were randomized at the beginning of the reinduction phase to receive (second exposure) L-ASE twice a week at conventional doses (4 doses) or HD-L-ASE (20 weekly doses given during the reinduction and maintenance phases).
Drug products
Commercially available E. chrysanthemi L-ASE (Erwinase, Speywood Pharmaceuticals Ltd., Maidenhead, England) was used for all patients. The drug was reconstituted with 0.9% sodium chloride solution and administered intramuscularly.
Sample collection
Depending on the treatment schedule, blood samples were drawn 3, 4 or 7 days after the administration of L-ASE, just prior to the subsequent dose, and immediately placed in heparin-containing tubes. In 7 cases, treated weekly with HD-L-ASE, samples were also obtained 3 days following the administration of the drug.
The CSF samples were obtained, when intrathecal chemotherapy was scheduled, simultaneously with blood samples from 24 patients; prior to analysis the samples were stored in cryotubes (NUNC A-S, Roskilde, Denmark) at -80 "C.
For the experiment on residual L-ASE activity and L-ASE inhibitors, blood samples were obtained from 18 patients 7 days after administration of HD-L-ASE; from 4 patients 3 days after HD-L-ASE; from 3 patients 3 days after a dose of 10,000 IU/sqm (in 2 during induction and in one during the reinduction phase). For every assay 3 samples of plasma from healthy volunteers were also utilized as controls.
Determination of plasma L-ASN levels
As previously described [9] , the plasma levels of L-ASN were determined by the difference between its concentration in the whole blood and in blood cells. To deproteinize the sample and rapidly inactivate L-ASE, SSA (10% w/v) was added to an aliquot of blood (2 ml) immediately after sampling. In a second aliquot of blood (2 ml) cells were first separated from plasma and immediately thereafter deproteinized with SSA. The presence of L-ASE in plasma during centrifugation has no relevant effect on L-ASN intracellular content since L-ASN levels in cells are slow to follow changes in plasma [9|. The deproteinized samples, stored at -80 *C before analysis, were analyzed by HPLC after precolumn derivatization with o-phthaldialdehyde, as previously described [12] . Determination of plasma L-ASN levels by this method had a limit of detection of 1.0 Hg/ml.
Determination of CSF L-ASN levels
Since L-ASE does not cross the blood brain barrier, L-ASN levels in the CSF were measured without using the SSA procedure. One ml of each sample was concentrated 10-fold by overnight freeze-drying and addition of 0.1 ml of saline solution. Samples were then vortexed, centrifuged at 1500 rpm for 3 min and thereafter analyzed by HPLC (see above). The detection limit was 20 ng/ml CSF.
Assay to evaluate residual activity or deactivation of L-ASE in the plasma
Blood samples were immediately centrifuged to separate 2 ml of plasma. An aliquot of 0.5 ml was deproteinized. Plasma was then frozen at -80 'C until the day of the experiment. As described in the first step of Table 2 , the deproteinized aliquot was used to determine L-ASN concentration; the limit of detection was 0.2 ng/ml. In the second step 30 ng of L-ASN were added to the 1.5 ml of remaining plasma and after a 30-min incubation at 37 'C, an aliquot of 0.5 ml of this sample was deproteinized and used to measure L-ASN concentration; the aim of this step was to assess residual L-ASE activity in the patients' plasma (in this case the added L-ASN would have been hydrolyzed). For the third step 0.01 IU of L-ASE was added to the remaining 1.0 ml of plasma and after a 30-min incubation at 37 "C an aliquot of 0.5 ml was deproteinized and used to determine the L-ASN concentration; the aim of this step was to assess the deactivation of the added L-ASE (in this case the added L-ASE would not hydrolyze the residual L-ASN). The concentration of 0.01 IU L-ASE was chosen since preliminary experiments showed in all samples (from patients and controls) a complete hydrolysis after the addition of 0.1 RJ/ml of L-ASE, while none of the samples showed hydrolysis with the addition of 0.001 IU/ml of L-ASE. Table 3 shows L-ASN plasma levels found 3 days after 1-2 or 3-5 or 6-8 doses of L-ASE (10,000 IU/sqm) Table 2 . In vitro experiment to test for the presence of residual activity and/or deactiviation of L-ASE in patients' plasma. Table 3 . L-ASN plasma levels (ng/ml) in patients treated with L-ASE 10,000 IU/sqm every 3 days during the induction phase. The levels are measured at the 3rd day.
Results
Plasma L-ASN levels
Plasma
Steps AIM: to assess 2 ml 1st: -0.5 ml deproteinized to L-ASN depletion measure L-ASN concentration during induction phase (1st exposure). In the first, second and third groups 83%, 69% and 89%, respectively, of the patients had levels of L-ASN below the detection limit As shown in Table 4 , during reinduction phase (second exposure to L-ASE given at 10,000 IU/sqm twice a week) only 3 of 12 patients (25%) exhibited L-ASN concentration < 1 ng/ml (median value 3.66 ng/ml). Table 5 shows the L-ASN plasma levels found 7 days after administration of 1-2, 3-8, 9-14 and 15-20 weekly doses of HD-L-ASE (25,000 IU/sqm, second or third exposure to the drug). Percentages of patients with a level of L-ASN <1 [ig/ml were 21%, 38%, 29% and 33%, respectively; the median values of L-ASN levels in these four groups were 4.52, 3.86, 3.82 and 2.63 (ig/ml, respectively; in 7 of these patients (treated weekly with HD-L-ASE), the L-ASN levels were also investigated 3 days after administration of the drug ( Figure 1) ; L-ASN was below the detection limit in the 2 patients who, as expected, were depleted on day 7, and in only 2 of the 5 not depleted on the 7th day.
Six patients presented with allergic reactions during HD-L-ASE treatment; none of them had L-ASN plasma concentrations below the limit of detection.
In vitro L-ASE deactivation by patients' plasma
As shown in Figure 2 , two groups of patients were identified. Part A shows the results in patients who were not depleted during L-ASE treatment. In these subjects no residual L-ASE activity was found; high levels of L-ASN were found after the incubation period with L-ASN (as in the controls); following the addition of the enzyme, the hydrolysis was very small compared to that observed in controls. Part B shows that, as expected and in contrast to the findings in controls, there was still L-ASE activity in patients in whom L-ASN depletion was observed during L-ASE treatment, as indicated by the rapid and complete hydrolysis of the L-ASN added in step 2. Obviously, L-ASN level was zero also after the incubation with L-ASE in these cases.
Part C shows the results of the experiment performed with healthy volunteers' plasma in parallel to each patient assay. Figure 3 shows L-ASN levels in plasma and in CSF, obtained at the same time, in 24 patients treated with L-ASE. Although the limited number of cases does not allow a threshold value to be defined, it is possible to observe a relationship between levels of L-ASN in the CSF and plasma. In fact, in patients with L-ASN plasma levels below the limit of detection of the method (i.e., < 1 ng/ml) the mean value (± SD) of CSF L-ASN levels was 198 ng/ml (± 141) (range 20-380). Conversely, in cases with L-ASN plasma levels higher than 1 u-g/ml the mean value (± SD) of L-ASN in CSF was 748 ng/ml (± 237) (range 350-1000).
Levels of L-ASN in plasma and CSF
Clinical findings
None of the patients in this study presented with clinical pancreatitis or diabetes requiring insulin therapy, or severe hepatic dysfunction. Allergic reactions were seen in only 6 children and in all of them during HD-L-ASE treatment (second exposure to the drug). Four patients (nos. 22, 26, 40 and 48) presented local reactions (urticaria or swelling after doses 1,2,6, and 18); 2 patients (nos. 18 and 39) developed local + systemic reactions (urticaria or swelling + cardiorespiratory impairment, respectively, after doses 1 and 3). HD-L-ASE treatment was discontinued in patients 22, 39 and 40. Patient number 15 developed a pulmonary thromboembolism after the third dose of L-ASE of the induction phase, which rapidly resolved under heparin treatment; the L-ASE treatment was discontinued.
Discussion
Most data reported in the literature on the depletion of L-ASN plasma levels have been obtained in patients receiving L-ASE derived from E. coli [5, 8] . Possible differences between the effects of the L-ASE from E. chrysanthemi and from E. coli can arise from differences in their pharmacokinetics, since the product derived from E. chrysanthemi disappears from plasma much faster than that derived from E. coli, with mean half-lives of 16 and 31 hours, respectively [7] .
The present study shows that L-ASE derived from E. chrysanthemi given at the dose of 10,000 IU/sqm q 3 days renders possible L-ASN plasma depletion in approximately 80% of the patients during the first exposure (induction phase). Overall, depletion of plasma L-ASN was observed in only approximately 25% of the patients during the reinduction or maintenance phases L-ASN plasma levels (ug/ml) 10 12 Figure 3. L-ASN CSF levels versus L-ASN plasma levels (u.g/ml). The solid line shows the limit of the method when plasma levels were measured.
(second or third exposure). These results were obtained from different patients at different time points. The differences in plasma L-ASN depletion found between the first and the succeeding exposures to the drug were, however, very striking; it can thus be concluded that, independently of the study design, the effectiveness of the drug is reduced when given for the second or third time. These results are in accord with data recently obtained by other investigators [13] . The lack of depletion of plasma L-ASN during HD-L-ASE (25,000 IU/ sqm) administration suggests that the 7-day intervals may be too long. However, 3 of 5 patients not depleted by day 7 were also not depleted only 3 days after administration of HD-L-ASE, providing further evidence that the drug may be less effective when given for a second or third time. Although the mechanisms involved have yet to be fully elucidated, this process is probably due to the presence of inactivating factors in the plasma rather than to pharmacokinetic effects (e.g., increased clearance of L-ASE after repeated treatments) or increased tissue production of L-ASN. The results reported in this paper show in fact that there are factors which can rapidly inactivate the enzyme in the plasma of patients in whom L-ASN depletion is not found (Figure 2 ). Studies should be carried out to determine whether these factors could be antibodies, as has been observed in the course of treatment with the E. coli product [14] .
Results on L-ASN depletion in the CSF are in accord with other findings reported in the literature [15] and suggest that L-ASE treatment is potentially effective for the CNS localization of ALL. Although the number of cases investigated did not allow a precise quantitative correlation to be established between plasma and CSF L-ASN levels, this study indicates that when L-ASN plasma levels are detectable there are relatively high CSF L-ASN levels as well.
In summary, this study demonstrates that L-ASE from E. chrysanthemi provides L-ASN depletion in the majority of children when the drug is given for the first time. The most relevant finding, however, is that in most cases retreatment of patients with L-ASE derived from E. chrysanthemi is less effective in depleting L-ASN plasma levels. Investigations should be carried out to determine whether L-ASN plasma depletion could be obtained in more cases by administering the enzyme more frequently (e.g., every two days) or at higher doses in the first exposure.
It also remains to be clarified whether L-ASE derived from E. coli or conjugated with polyethylene-glycole could be effective in obtaining L-ASN plasma depletion in patients previously treated with L-ASE derived from E. chrysanthemi and whether differences in L-ASN depletion have a clinical impact.
